We hypothesized that increased CRLF2-level in combination with a mutation in JAK2 pathway genes could be sufficient to activate wtRAS protein in the absence of RAS mutations, as a mechanism to explain the mutual exclusion of JAK2 and RAS/MAPK mutations in DS-ALL. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.